Evaxion A/S (EVAX)
NCM · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Evaxion A/S
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 37K | 7.5M | 0.00 | 0.00 |
| Operating Income | -4.3M | 3.0M | -4.1M | -3.8M |
| Net Income | -4.8M | 4.6M | -5.9M | -3.6M |
| Diluted EPS | $-1.00 | $0.50 | $-1.00 | $-0.50 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 73K | 3.3M | 7.5M |
| Operating Income | -25.3M | -22.2M | -14.7M | -9.2M |
| Net Income | -23.2M | -22.1M | -10.6M | -7.7M |
| Diluted EPS | $-49.00 | $-40.50 | $-10.00 | $-1.00 |